TY - JOUR
T1 - Operationalizing protocol differences for EADC-ADNI manual hippocampal segmentation
AU - Boccardi, Marina
AU - Bocchetta, Martina
AU - Ganzola, Rossana
AU - Robitaille, Nicolas
AU - Redolfi, Alberto
AU - Duchesne, Simon
AU - Jack, Clifford R.
AU - Frisoni, Giovanni B.
AU - Bartzokis, George
AU - Csernansky, John G.
AU - De Leon, Mony J.
AU - Detoledo-Morrell, Leyla
AU - Killiany, Ronald J.
AU - Lehericy, Stephane
AU - Malykhin, Nikolai
AU - Pantel, Johannes
AU - Pruessner, Jens C.
AU - Soininen, Hilkka
AU - Watson, Craig
N1 - Funding Information:
N. R. and S. D. have received funding support from the Ministère du Développement Économique, de l'Innovation et de l'Exportation du Québec .
Funding Information:
The Alzheimer's Association has provided logistic support for the update meetings of the project in Toronto (April 2010), Honolulu (July 2010 and April 2011), and Paris (July 2011). Wyeth , part of the Pfizer group , and Lilly have provided unrestricted grants in support of the work reported in this article. A follow-up project has been funded by the Alzheimer's Association : A Harmonized Protocol for Hippocampal Volumetry: An EADC-ADNI Effort (grant no. IIRG -10-174022 ). The project principle investigator (PI) is Giovanni B. Frisoni, IRCCS Fatebenefratelli, Brescia, Italy; the co-PI is Clifford R. Jack, Mayo Clinic, Rochester, MN; the Statistical Working Group is led by Simon Duchesne, Laval University, Quebec City, Canada; and project coordinator is Marina Boccardi, IRCCS Fatebenefratelli, Brescia, Italy. European Alzheimer's Disease Consortium (EADC) centers (local principal investigators) are IRCCS Fatebenefratelli, Brescia, Italy (G. B. Frisoni); University of Kuopio and Kuopio University Hospital, Kuopio, Finland (H. Soininen); Höpital Salpètriere, Paris, France (B. Dubois and S. Lehericy); University of Frankfurt, Frankfurt, Germany (H. Hampel); University Rostock, Rostock, Germany (S. Teipel); Karolinska Institutet, Stockholm, Sweden (L.-O. Wahlund); Department of Psychiatry Research, Zurich, Switzerland (C. Hock); Alzheimer Centre, Vrije University Medical Centre, Amsterdam, The Netherlands (F. Barkhof and P. Scheltens); the Dementia Research Group Institute of Neurology, London, UK (N. Fox); and NEUROMED, Centre for Neuroimaging Sciences, London, UK (A. Simmons). Alzheimer's Disease Neuroimaging Initiative (ADNI) centers are Mayo Clinic, Rochester, MN (C. R. Jack); University of California at Davis, Davis, CA (C. DeCarli); University of California at Los Angeles (UCLA), Los Angeles, CA (G. Bartzokis); University of California at San Francisco (UCSF), San Francisco, CA (M. Weiner and S. Mueller); Laboratory of NeuroImaging, UCLA, Los Angeles, CA (P. M. Thompson); Rush University Medical Center, Chicago, IL (L. deToledo-Morrell); Rush Alzheimer's Disease Center, Chicago, IL (D. Bennet); Northwestern University, Chicago, IL (J. Csernansky); Boston University School of Medicine, Boston, MA (R. Killiany); John Hopkins University, Baltimore, MD (M. Albert); the Center for Brain Health, New York, NY (M. De Leon); and Oregon Health & Science University, Portland, OR (J. Kaye). Other centers are McGill University, Montreal, Quebec, Canada (J. Pruessner); University of Alberta, Edmonton, Alberta, Canada (R. Camicioli and N. Malykhin); Department of Psychiatry, Psychosomatic, Medicine & Psychotherapy, Johann, Wolfgang Goethe-University, Frankfurt, Germany (J. Pantel); Wayne State University, Detroit, MI (C. Watson); and the Institute for Ageing and Health, Wolfson Research Centre, Newcastle General Hospital, Newcastle, UK (J. O'Brien). Population-based studies include PATH Through Life, Australia (P. Sachdev and J. J. Maller); the SMART-Medea Study, The Netherlands (M. I. Geerlings); and the Rotterdam Scan Study, The Netherlands (T. denHeijer). The Statistical Working Group includes the Fatebenefratelli Association for Biomedical Research, San Giovanni Calibita - Fatebenefratelli Hospital, Rome, Italy (P. Pasqualetti); Laval University, Quebec City, Canada (S. Duchesne); and the Montreal Neurological Institute, McGill University, Montreal, Canada (L. Collins). The advisor for clinical issues include P. J. Visser, Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands; EADC PIs include B. Winbald, Karolinska Institute, Sweden; and Ll Froelich, Central Institute of Mental Health, Mannheim, Germany. Advisors for dissemination and education include G. Waldemar, Copenhagen University Hospital, Copenhagen, Denmark; the ADNI PI is M. Weiner, UCSF, San Francisco, CA. Advisors for population Studies include L. Launer, National Institute on Aging (NIA), Bethesda, MD; and W. Jagust, University of California, Berkeley, CA.
Publisher Copyright:
© 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
PY - 2015
Y1 - 2015
N2 - Background: Hippocampal volumetry on magnetic resonance imaging is recognized as an Alzheimer's disease (AD) biomarker, and manual segmentation is the gold standard for measurement. However, a standard procedure is lacking. We operationalize and quantitate landmark differences to help a Delphi panel converge on a set of landmarks. Methods: One hundred percent of anatomic landmark variability across 12 different protocols for manual segmentation was reduced into four segmentation units (the minimum hippocampus, the alveus/ fimbria, the tail, and the subiculum), which were segmented on magnetic resonance images by expert raters to estimate reliability and AD-related atrophy. Results: Intra- And interrater reliability were more than 0.96 and 0.92, respectively, except for the alveus/fimbria, which were 0.86 and 0.77, respectively. Of all AD-related atrophy, the minimum hippocampus contributed to 67%; tail, 24%; alveus/fimbria, 4%; and the subiculum, 5%. Conclusions: Anatomic landmark variability in available protocols can be reduced to four discrete and measurable segmentation units. Their quantitative assessment will help a Delphi panel to define a set of landmarks for a harmonized protocol.
AB - Background: Hippocampal volumetry on magnetic resonance imaging is recognized as an Alzheimer's disease (AD) biomarker, and manual segmentation is the gold standard for measurement. However, a standard procedure is lacking. We operationalize and quantitate landmark differences to help a Delphi panel converge on a set of landmarks. Methods: One hundred percent of anatomic landmark variability across 12 different protocols for manual segmentation was reduced into four segmentation units (the minimum hippocampus, the alveus/ fimbria, the tail, and the subiculum), which were segmented on magnetic resonance images by expert raters to estimate reliability and AD-related atrophy. Results: Intra- And interrater reliability were more than 0.96 and 0.92, respectively, except for the alveus/fimbria, which were 0.86 and 0.77, respectively. Of all AD-related atrophy, the minimum hippocampus contributed to 67%; tail, 24%; alveus/fimbria, 4%; and the subiculum, 5%. Conclusions: Anatomic landmark variability in available protocols can be reduced to four discrete and measurable segmentation units. Their quantitative assessment will help a Delphi panel to define a set of landmarks for a harmonized protocol.
UR - http://www.scopus.com/inward/record.url?scp=84933501125&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84933501125&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2013.03.001
DO - 10.1016/j.jalz.2013.03.001
M3 - Article
C2 - 23706515
AN - SCOPUS:84933501125
SN - 1552-5260
VL - 11
SP - 184
EP - 194
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 2
ER -